* Enzon Inc., of Piscataway, N.J., and Schering Corp., of Madison,N.J., revised their worldwide agreement for Peg-Intron A, a modifiedform of Schering's Intron A (interferon alpha-2b). Schering invested$4 million in Enzon, half of which was equity, and will pay another$1 million. In return it obtained know-how and acquiredmanufacturing rights.

* ImmuLogic Pharmaceutical Corp., of Waltham, Mass., adopted ashareholder rights plan. It said the plan was not in response to aspecific takeover threat or proposal.

* Japan Tobacco Inc., of Tokyo, said it developed a technology tointroduce genes into maize by using the microorganismAgrobacterium.

* OxiGene Inc., of New York, adjusted the price of the warrantsissued in connection with its initial public offering, reducing the pricefrom $9 to $8.39.

* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., made a new drugsubmission in Canada seeking approval of Rilutek as a treatment foramyotrophic lateral sclerosis.

* Sheffield Medical Technologies Inc., of New York, entered into anoption and sponsored research agreement with Children's Hospital,of Boston, to develop clotrimazole and its metabolites for sickle cellanemia.

* Shreve Biotech, of Shreveport, La., was awarded a $100,000 smallbusiness grant to develop methods to enhance the immune responseagainst viral antigens.

* Tanox Biosystems Inc., of Houston, started a Phase I/IIa trial ofAD-519, a neutralizing monoclonal antibody to the C4 region ofgp120, an envelope glycoprotein of HIV.

* Telios Pharmaceuticals Inc., of San Diego, said all shareholdersvote in favor of the company's proposed reorganization plan.

* The Immune Response Corp., of Carlsbad, Calif., receivedclearance to test its rheumatoid arthritis therapy, which is designed toimmunize against T cells believed implicated in the disease, in a 90-patient Phase II trial.

* Zynaxis Inc., of Malvern, Pa., said it was awarded up to $750,000for a two-year Phase II small business innovation research grant toevaluate the coupling of its Zyn-Linker delivery molecules to heparin.

(c) 1997 American Health Consultants. All rights reserved.